Certolizumab pegol vs placebo
Failure to maintain clinical remission at end of study · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
- Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes onlyRR 0.73 [0.63, 0.85]Studies not reportedModerate